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1. Introduction 
For early stage (stage I) epithelial ovarian cancer (EOC) surgery may be the sole curative 
therapy. However, the vast majorities of cases are diagnosed in more advanced stages and 
need a multimodal treatment strategy. Therefore, in stage II and higher, surgery with a 
cytoreductive intent, (i.e. to remove as much as possible the macroscopic disease from the 
peritoneal surfaces in adjunct to bilateral salpingo-oophorectomy) is not curative by itself, 
but has to be supplemented by cytotoxic therapy. This is mainly administered as 
intravenously (i.v.) chemotherapy or sometimes as intraperitoneal (i.p.) chemotherapy. 
Although there are trials using whole abdominal or moving-strip external beam 
radiotherapy as adjuvant therapy (Einhorn et al., 2003) or i.p. radiotherapy with colloid 
preparations of 198Au or 32P (Rosenhein et al., 1979; Varia et al., 2003) these have so far not 
presented results to merit a place in the normal therapeutic arsenal, and long term toxicity 
from normal tissues is a major concern.  
Despite extensive cytoreductive surgery and modern chemotherapy, with complete 
remissions (CR) at second look laparotomy (SLL) and normalisation of the serum marker 
cancer antigen 125 (CA-125), approximately 70% of the patients in stage III recur and will 
eventually succumb to their disease. The recurrence pattern is normally the development of 
ascites due to progression of treatment resistant cells growing as peritoneal microscopic 
deposits. From this incurable situation the progression is dominated by a continuous 
accumulation of ascites with intestinal adhesions and bowel obstructions. This progression 
can often be temporarily halted by palliative chemotherapy, or in special occasions, local 
external beam radiotherapy, but will in any event, eventually lead to a great deal of 
suffering and pain from above the abdominal cavity pathology. 
Since the negative impact on survival and the suffering associated with uncontrolled spread 
in the abdominal cavity, efforts have been directed to develop more effective local 
treatments. Such a local more aggressive treatment strategy has proven effective as 
chemotherapy injected locally in the peritoneal cavity (i.p.) could show as a reduction in 
recurrences and a decrease in mortality, although at the expense of clearly increased toxicity 
(Jaaback & Johnson, 2009). The use of 90Y, conjugated to a monoclonal antibody (mAb) and 
studied in a large prospective randomised controlled study, unfortunately did not 
demonstrate a benefit (Oei et al., 2007; Verheijen et al., 2006).  
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These negative results on overall survival of i.p. radioimmunotherapy (RIT) using the ǃ-
emitter 90Y, conjugated to a mAb, are a concern (Verheijen et al., 2006), even if a decreased 
local i.p. recurrence has been seen (Oei et al., 2007). A number of important issues relating to 
this trial including the physical properties of the used nuclide will be discussed in depth, 
which might give clues to optimization of future trials of intraperitoneal RIT. 
2. Radionuclides 
In targeted radionuclide therapy the cytotoxic effect is mediated by a radionuclide, brought 
to the target by the targeting construct (Elgqvist et al., 2010). Below is a list of the 
radionuclides used, in both animal and clinical studies. The list includes a presentation of 
their physical characters, and in which studies they have been used.  
225Ac (Actinium-225). 225Ac decays with a half-life of 10 days and emits four ǂ-particles in a 
serial decay. The ǂ-particle emitted from 225Ac has an energy of 5.8 MeV (mean linear 
energy transfer [LET] ≈ 120 keV/µm) and the daughters are 221Fr (T½ = 4.8 min, E = 6.3 MeV, 
mean LET ≈ 118 keV/µm), 217At (T½ = 32.3 ms, E = 7.1 MeV, mean LET ≈ 109 keV/µm), and 
213Bi (T½ = 45.6 min, E = 8.4 MeV, mean LET ≈ 99 keV/µm). The ǂ-decays are accompanied 
by gamma(Ǆ)-radiation, enabling scintigraphy and dosimetry. 225Ac has been used in one 
animal study (Borchardt et al., 2003). 
 211At (Astatine-211). 211At (an ǂ-particle emitter) is cyclotron produced via the nuclear 
reaction 207Bi(ǂ,2n)211At. 211At decays with a half-life of 7.2 hours in 2 ways: (i) via emission 
of an ǂ-particle (E = 5.9 MeV) to 207Bi, or (ii) via an electron capture process to 211Po. 207Bi 
decays with a half-life of 31.6 y to 207Pb (stable). 211Po decays with a half-life of 0.5 s to 207Pb 
via ǂ-particle emission (E = 7.4 MeV). The 5.9- and 7.4-MeV ǂ-particles have a mean LET of 
~122 and ~106 keV/µm and a particle range in tissue of ~48 and ~70 µm, respectively. The 
decays are accompanied by Ǆ-radiation, enabling scintigraphy and dosimetry. 211At has been 
used in animal studies (Andersson et al., 1999, 2000a, 2000b, 2001; Bäck et al., 2005; Elgqvist 
et al., 2005a, 2005b, 2006a, 2006b, 2006c, 2009a, 2009b; Steffen et al., 2006) and in one clinical 
study (Andersson et al., 2009). 
213Bi (Bismuth-213). 213Bi (an ǂ-particle emitter) is available via a generator based technology 
due to its relatively long-lived parent radionuclide, 225Ac. 213Bi decays with a half-life of 45.6 
min to 209Bi (stable) during which it emits an ǂ-particle of 8.4 MeV (mean LET and particle 
range in tissue: ~99 keV/µm and ~89 µm, respectively). The ǂ-particle emission is 
accompanied by Ǆ-radiation. 213Bi has been used in animal studies (Knör et al., 2008; Song et 
al., 2007). 
90Y (Yttrium-90). 90Y is chemically similar to the lanthanoids and decays with a half-life of 64 
h by the emission of electrons (ǃ) with a maximum energy of ~2.2 MeV (Emean = 933 keV). 
The emitted electrons have a maximum range in tissue of ~12 mm (mean range ≈ 4 mm) and 
a mean LET ≈ 0.2 keV/µm. Due to the emission of Bremsstrahlung, scintigraphy is feasible. 
90Y has been used in one animal study (Buchsbaum et al., 2005) and in clinical studies 
(Alvarez et al., 2002; Epenetos et al., 2000; Grana et al., 2004; Hird et al., 1990; Hnatowich et 
al., 1988; Maraveyas et al., 1994; Oei et al., 2007; Rosenblum et al., 1999; Stewart et al., 1990; 
Verheijen et al., 2006). 
177Lu (Lutetium-177). This radionuclide has a half-life of 6.7 d and decays by the emission 
of ǃ--particles with a maximum energy of 497 keV (Emean = 133 keV), which have a range 
in tissue of ~2 mm (mean range ≈ 0.2 mm), and a mean LET < 0.1 keV/µm. It also emits Ǆ-
radiation (208 keV). 177Lu can be produced in large scale owing to the high thermal 
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neutron capture cross-section of 176Lu (2100 barn) using moderate flux reactors. 177Lu has 
been used in animal studies (Buchsbaum et al., 1999, 2005; Persson et al., 2007; Tolmachev 
et al., 2007) and in clinical studies (Alvarez et al., 1997; Epenetos et al., 1987; Meredith et 
al., 1996, 2001).  
131I (Iodine-131). 131I has a half-life of 8 d and decays by the emission of ǃ-particles with a 
maximum energy of 807 keV (Emean = 182 keV, mean LET ≈ 0.1 keV/µm), which have a 
maximum range in tissue of ~3.6 mm (mean range ≈ 0.4 mm). It emits Ǆ-radiation (364 keV) 
enabling scintigraphy and dosimetry. 131I has been used in animal studies (Kievit et al., 1996; 
Molthoff et al., 1992; Turner et al., 1998) and in clinical studies (Buchsbaum et al., 1999; Buijs 
et al., 1998; Buist et al., 1993; Colcher et al., 1987; Crippa et al., 1995; Epenetos et al., 1987; 
Mahé et al., 1999; Molthoff et al., 1992, 1997; Muto et al., 1992; Stewart et al., 1989a, 1989b; 
Van Zanten-Przybysz et al., 2000, 2001). 
186Re (Rhenium-186) and 188Re (Rhenium-188). 186Re has a half-life of 3.7 d and decays by 
emitting ǃ-particles having a maximum energy of 1.07 MeV (mean LET ≈ 0.1 keV/µm), 90% 
of it delivered within ~1.8 mm. 186Re also emits Ǆ-radiation. 186Re has been used in clinical 
studies (Breitz et al., 1995; Jacobs et al., 1993). 188Re has a half-life of 17 h and decays by 
emitting ǃ-particles having a maximum energy of 795 keV (mean LET ≈ 0.1 keV/µm). The 
emitted Ǆ-radiation enables scintigraphy and dosimetry. 188Re has been used in one clinical 
study (Macey & Meredith, 1999). 
3. Targeting constructs 
In developing treatment strategies against EOC based on the concept of targeted 
radionuclide therapy several candidates as targeting constructs have been evaluated. Below 
follow a compilation of the main targeting constructs that have been used for bringing the 
radionuclide to the target, in animal as well as in clinical studies. 
HMFG1 is a murine monoclonal antibody (mAb) which is directed to an epitope of the 
MUC1 gene product. MUC1 is a large, heavily glycosylated mucin (>400 kDa) expressed on 
the apical surface of the majority of secretory epithelial cells (Gendler, 2001). MUC1 is 
overexpressed in 90% of adenocarcinomas, including cancers of the ovary (Mukherjee et al., 
2003). The extracellular portion of the MUC1 protein mainly consists of a variable number of 
highly conserved 20 amino acid repeats (Verheijen et al., 2006). HMFG1 has been used in 
clinical studies (Epenetos, et al., 1987; Verheijen et al., 2006). 
HMFG2 is a murine mAb that is directed towards a large mucin-like molecule normally 
produced by the lactating breast. The mAbs react with similar components expressed by the 
majority (>90%) of ovarian, breast and other carcinomas (Arklie, et al., 1981). The HMFG2 
epitope is generally expressed at a higher level in tumors (Burchell et al., 1983). HMFG2 has 
been used in one clinical study (Epenetos et al., 1987). 
AUA1 is a murine IgG1 mAb that binds to an antigen expressed by a wide range of 
adenocarcinoma, including the majority (>90%) of carcinomas of the ovary. The antigen is a 
40 kDa glycoprotein (Epenetos et al., 1982). AUA1 has been used in one clinical study 
(Epenetos et al., 1987). 
H17E2 is a murine IgG1 mAb that is directed to placental and placental-like alkaline 
phosphatase (PLAP) (Travers & Bodmer, 1984). This enzyme is expressed as a surface 
membrane antigen (~67 kDa) of many neoplasms, including 60%–85% of ovarian 
carcinomas (Benham et al., 1978; Sunderland et al., 1984). H17E2 has been used in one 
clinical study (Epenetos et al., 1987). 
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Hu2PLAP is a human IgG1 κ mAb that has the same specificity as the murine H17E2 mAb 
described above. Hu2PLAP has been used in one clinical study (Kosmas et al., 1998).  
H317 is a murine IgG mAb developed after immunisation with syncytiotrophoblast microvilli 
preparations from term placenta. It is specific for the L-phenylalanine inhibitable placental 
alkaline phosphatase (PLAP). H317 has been used in one clinical study (Kosmas et al., 1998).  
Trastuzumab (Herceptin; Genentech, South San Francisco, CA) is a humanized IgG1 mAb 
that recognizes the extracellular domain of the HER-2/neu oncoprotein (Carter et al., 1992). 
Trastuzumab has been used in one animal study (Borchardt et al., 2003). 
Pertuzumab is a human mAb binds to the dimerization domain II of HER-2. Pertuzumab is 
based on the human immunoglobulin IgG1 κ framework sequences, and is produced in 
Chinese hamster ovary cells. It has been used in one animal study (Persson et al., 2007). 
B72.3 is a murine mAb that has been shown to be immunoreactive with the glycoprotein 
complex TAG-72 (>200 kDa) with the characteristics of a mucin (Johnson et al., 1986; Thor et 
al., 1986; Wolf et al., 1989). TAG-72 expression has been shown in the majority of ovarian 
carcinomas tested (Nuti et al., 1982). B72.3 has been used in clinical studies (Colcher et al., 
1987; Rosenblum et al., 1999). 
CC49 is a murine mAb is a high-affinity murine product that reacts with the tumor-
associated glycoprotein TAG-72, which is expressed by the majority of common epithelial 
tumors (Schlom et al., 1990). CC49 has been used in one animal study (Buchsbaum et al., 
2005) and in clinical studies (Alvarez et al., 1997, 2002; Buchsbaum et al., 1999; Macey et al., 
1999; Meredith et al., 1996). 
OC125 is a murine mAb that is directed against the tumor marker CA-125, and has been 
used in clinical studies (Hnatowich et al., 1988; Mahé et al., 1999; Muto et al., 1992). 
MOv18 is a murine mAb that recognizes and reacts with a surface antigen, which is a 
membrane folate-binding glycoprotein of 38 kDa expressed on approximately 90% of all 
human ovarian carcinomas (Boerman et al., 1991; Campbell et al., 1991; Miotti et al., 1987). 
MOv18 (murine and in some cases chimeric) has been used in animal studies (Andersson et 
al., 1999, 2000a, 2000b, 2001) and in clinical studies (Buijs et al., 1998; Buist et al., 1993; 
Molthoff et al., 1992, 1997; Van Zanten-Przybysz et al., 2000, 2001). 
MX35 is a murine IgG1 mAb directed towards a cell-surface glycoprotein of ~95 kDa on 
OVCAR-3 cells (Welshinger et al., 1997) and is expressed strongly and homogeneously on 
~90% of human epithelial ovarian cancers (Rubin et al., 1993). The antigen recognized by 
MX35 is characterized as the sodium-dependent phosphate transport protein 2b (NaPi2b) 
(Yin et al., 2008). MX35 F(ab’)2 has been used in animal studies (Bäck et al., 2005; Elgqvist et 
al., 2006a, 2006b, 2006c, 2009a, 2009b) and in one clinical study (Andersson et al., 2009). 
NR-LU-10 is a IgG2b murine mAb that is reactive with a glycoprotein (~40 kDa) expressed 
on most carcinomas of epithelial origin (Goldrosen et al., 1990; Varki et al., 1984). NR-LU-10 
has been used in clinical studies (Breitz et al., 1995; Jacobs et al., 1993). 
A5B7 is an anti-CEA IgG1 mAb that has been used in one large-animal model (sheep) study 
(Turner et al., 1998). 
17-1A is a chimeric mAb is directed towards a ~39 kDa membrane-associated pancarcinoma 
glycoprotein (Edwards et al., 1986; Koprowski et al., 1979). It has been used in one animal 
study (Kievit et al., 1996). 
323/A3 is a murine mAb that is directed to a ~39 kDa membrane-associated pancarcinoma 
glycoprotein (same as 17-1A) (Edwards et al., 1986; Koprowski et al., 1979). It has been used 
in one animal study (Johnson et al., 1986). 
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hCTMO1 is an antibody that was constructed by taking the short hypervariable regions of 
the murine mAb CTMO1 and grafting them into a human IgG4. It is directed towards a 
glycoprotein expressed on malignant cells of epithelial origin (Baker et al., 1994; Zotter et al., 
1988). hCTMO1 has been used in one clinical study (Davis et al., 1999).  
OV-TL 3 is a murine IgG1 mAb that recognizes a cell-surface antigen highly expressed on 
>90% of ovarian carcinomas (Poels et al., 1986). It has been used in one clinical study (Buist 
et al., 1995). 
139H2 is a IgG1 mAb which binds to a protein determinant of episialin (Hilkens et al., 1988). 
139H2 has been used in one animal study (Molthoff et al., 1992). 
P-P4D is a targeting construct which is a pseudo-symmetrical covalent dimer of the 
monomeric peptide P-P4. It has been used in one animal study (Knör et al., 2008). 
PAI2 is a targeting construct that is a plasminogen activator inhibitor type 2 and which is a 
member of the serine protease inhibitor (Serpin) superfamily and forms SDS-stable 1:1 
complexes with urokinase plasminogen activator (uPA) (Song et al., 2007). It has been used 
in one animal study (Song et al., 2007). 
Affibody molecules are composed of alpha helices and lack disulfide bridges. Two such 
molecular constructs, (ZHER2:4)2 and (ZHER2:342)2 (~15 kDa) have been used in animal studies 
(Steffen et al., 2006a, 2006b; Tolmachev et al., 2007). 
4. Labeling chemistry 
In nuclear medicine targeted therapy all to date approved radiopharmaceuticals are based 
on ǃ-particle emitters. However, an increasing interest has been focused on ǂ-particle 
emitting radionuclides as they offer several advantages over the most commonly used ǃ-
emitters for the treatment of micro-tumors. Unlike medically applied therapeutic 
radionuclides that decay by medium- to high-energy ǃ-particle emissions leading to low-
LET radiation with particle ranges varying from 1 to 10 mm, ǂ-particle emitting 
radionuclides emit high-LET radiation in a small volume determined by the ǂ-particle 
ranges of 50–100 μm. Only a few ǂ-emitters fulfill the criteria for endoradiotherapeutic 
applications, the most studied being 211At, 212Bi, and 213Bi. All these nuclides decay by 100% 
ǂ-particle emission. Astatine-211 decays in two branches, 58% probability through electron 
capture to 211Po which in turn decays through an ǂ-particle emission (7.45 MeV) with a half-
life of 0.52 seconds to the stable 207Pb. The other branch (42%), resulting in an ǂ-particle of 
5.87 MeV, also ends in the stable 207Pb through the daughter 207Bi. The decay of 212Bi is very 
similar to the decay of 213Bi in terms of half-life and energy emitted (T½ for 212Bi = 60.6 min 
versus T½ for 213Bi = 45.6 min, mean Eǂ of both nuclides ≈ 8–8.5 MeV). However, while 213Bi 
can be isolated as pure nuclide from the 225Ac/213Bi generator, 212Bi is obtained in situ from 
the decay of 212Pb. Lead-212 decays to 212Bi with a half-life of 10.6 h. 
For stable attachment of metals such as 212Pb/212Bi or 213Bi to tumor specific targeting 
constructs an intermediate bifunctional chelating agent is required. A number of different 
chelating derivatives have been developed for conjugate labeling of various carrier 
molecules. Biological targeting constructs such as antibodies and peptides are commonly 
labeled with metal nuclides via chelating agents based on DTPA 
(diethylenetriaminepentaacetic acid) or DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid). Heat sensitive proteins are preferably labeled with the semi rigid open 
chain DTPA derivatives, e.g. CHX A``DTPA, due to the fast metal coordination reaction 
kinetics at room temperature. DOTA is a versatile chelating agent which shows strong 
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binding to a number of different metals, and the rigid structure give a metal-complex 
stronger than that of the corresponding complex to DTPA. However, chelating a metal to 
DOTA require heat or microwave assisted reaction condition, to be completed in reasonable 
times and with good yields, and are therefore more suitable for labeling to small molecules 
and peptides (Cordier et al., 2010).  
The most common functional leaving group of the reagent is succinimidyl ester which is 
directed towards free amines on proteins and peptides, mainly presented on the side chain 
of lysine. For example, an antibody of IgG class has a molecular weight of approximately 
150 kDa, and contains approximately 1200 amino acids, of which a number of lysine is 
randomly distributed. A lysine directed reagent conjugated to the antibody will therefore be 
non-specifically distributed in the protein structure, occasionally including the active 
antigen binding sites. Consequently the antigen binding capacity of the antibody may be 
affected when using lysine amine binding reagents. Site specific conjugation of antibodies 
can be achieved by targeting the sulfhydryl group on the side chain of cystein. In antibodies, 
cystein form disulfide bridges at specific sites within the antibody distant from the antigen 
binding site. The disulfide bridges can chemically be gently disrupted resulting in conjugate 
sites for a labelling reagent, e.g. malemido reagents. In this way the antigen binding of the 
conjugated antibody will not be compromised.  
Independent of chelating moiety the procedure for labeling is conjugation of the chelating 
derivative to the carrier molecule and then labeling to the conjugate. The direct chelating of 
the metal nuclide to the conjugate is a prerequisite when labeling with metal nuclides with 
very short half-lives, e.g. 213Bi. The other ǂ-emitting isotope of bismuth 212Bi is generated in 
the decay of 212Pb. Generally 212Pb or a mixture of 212Pb/212Bi is bound to a DOTA conjugate 
targeting construct. However, it has been reported that a fraction will be dechelated in the 
decay of 212Pb, leaving a free fraction of 212Bi (Su et al., 2005). 
Compared with the 213Bi, 211At is perhaps the most versatile mainly because of its longer half-
life, 7.2 h, which allow time for radiolabeling and quality control, and the time to distribute to 
the target cancer cells. Astatine is the heaviest element in the halogen family and since its 
discovery in 1940 (Corson et al., 1947) it has been proposed for use in nuclear medicine 
applications. Several research and preclinical studies utilising 211At for therapeutic nuclear 
medicine applications have been conducted, including the free halide, and 211At-labeled tumor 
specific targeting constructs (Zalutsky et al., 2000). Many of these studies include tumor 
specific monoclonal antibodies, as they constitute suitable carrier properties for a number of 
different malignancies (Anderson et al., 2000b). Encouraging preclinical results have been 
obtained in radioimmunotherapy with astatinated antibodies and two phase I studies have 
emerged from these studies (Andersson et al., 2009; Zalutsky et al., 2008). However, 211At 
requires a medium energy cyclotron for its production which is a major obstacle hampering 
clinical studies. And of the available cyclotrons having the capacity to produce 211At, only a 
few of those facilities actually produce 211At. Of the available cyclotrons having the capacity to 
produce 211At, only a few of those facilities actually produce 211At. In addition, one of the most 
demanding challenges in 211At-radioimmunotherapy applications has been the development 
of adequate chemical labeling procedures for the production of 211At-labeled antibodies at 
clinical levels of activity. Unlike direct iodination of proteins, astatine cannot be stably attached 
to unmodified antibodies (Visser et al., 1981). A number of different bifunctional labeling 
reagents for astatination of proteins have therefore been developed in which the common 
feature involves an electrophilic substitution reaction of organic tin as leaving group in the 
formation of an aryl-carbon- astatine bond, and a functional group for binding to proteins, 
www.intechopen.com
 Intraperitoneal Radionuclide Therapy – Clinical and Pre-Clinical Considerations 
 
237 
commonly N-succinimidyl esters (Wilbur et al., 1989; Yordanov et al., 2001; Zalutsky et al., 
1988). The radiochemistry is in general conducted in two steps, labeling of the reagent and 
conjugation of the labeled reagent to antibody. However, when using this strategy problems 
with yields and the final quality are frequently occurring, and have been recognised being due 
to radiolytic effects within the reacting solvents (Pozzi et al., 2007). Especially at high activity 
concentration conditions the ǂ-particle decay of astatine may during labeling result in a 
considerable absorbed dose to the reaction solvent which can affect the chemistry, i.e. self-
oxidation of astatine, decompose the precursor and/or alter the structural and biological 
integrity of the antibody. In fact, it has been reported that antibodies can be subjected to a 
maximum absorbed dose of approximately 1000 Gy without affecting its immunoreactivity 
(Larsen & Bruland, 1995).  
Similar to metal radiolabeling, in which a bifunctional chelate is conjugated to the protein 
prior to labeling, the ATE reagent can be conjugated to the protein prior to astatination. In 
this way problems related to absorbed dose to reaction volumes, and dependency on protein 
concentration, can be avoided. The resulting yield and specific activities can be kept high 
even at high activity reaction conditions (Lindegren et al., 2008). However, although stable 
in vitro it has been found that the aryl-carbon-astatine bond is not stable in vivo when bound 
to small carrier molecules, e.g. antibody fragments such as F(ab)-fragments and minibodies.   
Based on the higher strength of boron-astatine bonds (Kerr, 1977), new bifunctional reagents 
based on boron-cage structures, nido-carborane and closo-decaborate(2-) have been 
developed to increase the in vivo stability of  astatination of biomolecules (Wilbur et al., 
2004, 2009). The rout for synthesis of astatinated antibodies and fragments with the boron-
cage reagents is, as the in metal radiolabeling, conjugation of the reagent to the antibody and 
subsequently direct radiohalogenation of the immunoconjugate. Halogenation yields are 
therefore generally higher than the yields obtained in two step astatination of the ATE 
reagents. Greater stability to dehalogenation of the astatinated products labeled via boron-
cage chemistry has been confirmed (Wilbur et al., 2004). 
5. Animal studies 
Several animal studies investigating radionuclide therapy have been performed during the 
past couple of years. They have been investigating the pharmacokinetics, toxicity and 
therapeutic efficacy. The studies presented below comprise a selection of these studies using 
different radionuclides as well as different targeting constructs, and are paragraphed based 
on which radionuclide have been used, i.e. 225Ac, 211At, 213Bi, 90Y, 177Lu, or 131I. Some of the 
studies are not in an intraperitoneal setting, but have been mentioned because of their 
importance and relevance. 
5.1 225Ac-Trastuzumab 
One study has investigated the immunoreactivity, internalization, and cytotoxicity using 
SKOV-3 cells (Borchardt et al., 2003). The immunoreactivity was retained (50%–90%) and the 
radioimmunocomplex internalized into the cells (50% at 2 h). Various therapies were 
evaluated, using unlabeled trastuzumab and 8.1, 12.2, or 16.6 kBq of 225Ac-trastuzumab or 
225Ac-labeled control antibody. The therapies were given 9 d after tumor inoculation. 
Groups of control mice and mice administered unlabeled trastuzumab had median survivals 
of 33, 37 or 44 d, respectively. The median survival was 52–126 d using 225Ac-trastuzumab, 
and 48–64 d using the 225Ac-control mAb. Some deaths from toxicity occurred at the highest 
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activity levels. The study showed that i.p. administration of 225Ac-trastuzumab extended 
survival in mice at levels that produce no apparent toxicity. An advantage of 225Ac is that it 
emits a cascade of ǂ-particles, implying a very high cytotoxic effect if the ǂ-particle 
emissions occur in close vicinity to the cancer cell nuclei. The disadvantage is that when 
225Ac decays it will be separated from its targeting construct, making the remaining emitted 
ǂ-particles an unspecific irradiation that potentially could lead to both dosimetry and 
toxicity problems. 225Ac should therefore be used with caution in situations other than for 
example during intracavitary treatments or when the radioimmunocomplex is relatively 
rapid internalized into the cancer cells. 
5.2 211At-MOv-18, 211At-MX35 and 211At-Affibody 
Astatine-211 is a very promising radionuclide due to its half-life of 7.2 h and short particle 
range (~70 µm). A drawback is its limited availability due to the fact that it is cyclotron 
produced, and only a few cyclotrons world-wide produce 211At today. The potential 
problem with unspecific irradiation (as described above for 225Ac) is negligible due to the 
fact that the ǂ-particle emanating from the second decay route (from 211Po to 207Pb) occurs 
with a very short half-life (0.5 seconds), i.e. in close vicinity to the targeted cancer cell (Palm 
et al., 2004). Andersson et al. have performed studies investigating the pharmacokinetics 
and therapeutic efficacy of 211At-labeled mAbs (Andersson et al., 1999, 2000a, 2000b, 2001). 
In one of those studies the purpose was to compare the therapeutic efficacy of 211At-MOv18 
and 131I-MOv18 (Andersson et al., 2001). The study used OVCAR-3 cells growing i.p. in 
mice. Two weeks after the i.p. inoculation of 1 × 107 tumor cells twenty mice were treated 
i.p. with MOv18 labeled with either 211At (310–400 kBq) or 131I (5.1–6.2 MBq). The 
pharmacokinetics of the labeled antibody in tumor-free animals was studied and the 
resulting absorbed dose to bone marrow was estimated. When the mice were treated with 
211At-MOv18 nine out of ten mice were free of macro- and microscopic tumors compared to 
three out of ten when 131I-MOv18 was used. The equivalent dose to bone marrow was 2.4–
3.1 Sv from 211At-MOv18 and 3.4–4.1 Sv from 131I-MOv18. The study showed that the 
therapeutic efficacy of 211At-MOv18 was high, and superior to that using 131I-MOv18. 
Other studies using 211At-mAbs have also been completed (Bäck et al., 2005; Elgqvist et al., 
2005a, 2005b, 2006a, 2006b, 2006c, 2009a, 2009b). In one of those studies the purpose was to 
estimate the efficacy of RIT using 211At-MX35 F(ab’)2 or 211At-Rituximab F(ab’)2 (non-
specific) against differently sized ovarian cancer deposits on the peritoneum, and to 
calculate absorbed dose to tumors and critical organs (Elgqvist et al., 2006a). At 1–7 w after 
inoculation animals were i.p. treated with ~400 kBq 211At-MX35 F(ab’)2, ~400 kBq 211At-
Rituximab F(ab’)2, or unlabeled Rituximab F(ab’)2. Eight weeks after each treatment the 
mice were sacrificed and the presence of tumors and ascites was determined. When given 
treatment 1, 3, 4, 5, or 7 w after cell inoculation the tumor-free fraction (TFF) was 0.95, 0.68, 
0.58, 0.47, 0.26, and 1.00, 0.80, 0.20, 0.20, and 0.0 when treated with 211At-MX35 F(ab’)2 or 
211At-Rituximab F(ab’)2, respectively. The conclusion of the study was that treatment with 
211At-MX35 F(ab’)2 or 211At-Rituximab F(ab’)2 resulted in a TFF of 0.95–1.00 when the tumor 
radius was ≤30 µm. The TFF was decreased (TFF ≤ 0.20) for the non-specific 211At-Rituximab 
F(ab’)2 when the tumor radius exceeded the range of the ǂ-particles. The tumor specific 
mAb resulted in a significantly better TFF, for different tumor sizes, explained by a high 
mean absorbed dose (>22 Gy) from the activity bound to the tumor surface, probably in 
addition to some contribution from penetrating activity. 
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Another study (although not i.p.) evaluated the relative biological effectiveness (RBE) of 211At-
mAb (Bäck et al., 2005). The endpoint was growth inhibition (GI) of subcutaneous OVCAR-3 
xenografts. The animals received i.v. injections of 211At-MX35 F(ab’)2 (0.33, 0.65, and 0.90 
MBq). External irradiation of the tumors was performed with a 60Co source. To compare the 
biologic effects of the two radiation qualities, the mean value for GI was plotted for each tumor 
as a function of its corresponding absorbed dose. Exponential fits of these curves were made, 
and the absorbed doses required for a GI of 0.37 (D37) were derived, and also the RBE of 211At 
was determined. Absorbed doses in tumors were 1.35, 2.65, and 3.70 Gy. D37 was determined 
to 1.59 ± 0.08 Gy (mean ± SEM). Tumor growth after irradiation by the 60Co source resulted in 
a D37 of 7.65 ± 1.0 Gy. The RBE of 211At irradiation was calculated to be 4.8 ± 0.7 Gy.  
In yet another study (also not i.p.) HER-2 binding affibody molecules were labeled with 
211At, using the PAB and a decaborate-based linker, and the biodistribution in tumor bearing 
mice was investigated (Steffen et al., 2006a). Compared with a previous biodistribution with 
125I, the 211At biodistribution using the PAB linker showed higher uptake in lungs, stomach, 
thyroid and salivary glands, indicating release of free 211At. When the decaborate-based 
linker was used, the uptake in those organs was decreased, but instead, high uptake in 
kidneys and liver was found. The conclusion of the study was that affibody molecules have 
suitable blood-kinetics for targeted radionuclide therapy with 211At, the labeling chemistry 
however affects the distribution in normal organs to a high degree and needs to be 
improved to allow clinical use. 
5.3 213Bi-P-P4D and 213Bi-PAI2 
Bismuth-213 has a well established chemistry, is available via a generator, and has recently 
achieved an increased attention. A drawback is its short half-life (45.6 min), which necessitates 
a rapid specificity, once injected. Using 213Bi in intracavitary or i.p. applications, or using 
pretargeting techniques, could however overcome this potential problem. A study using 213Bi 
has been performed by Knör et al. developing peptidic radioligands, which targets cancer cell 
urokinase receptors (uPAR, CD87) (Knör et al., 2008). DOTA-conjugated, uPAR-directed 
ligands were synthesised. Biodistribution of 213Bi-P-P4D was analysed in mice 28 d after i.p. 
inoculation of OV-MZ-6 ovarian tumor cells in the absence or presence of the plasma expander 
gelofusine. Binding of 213Bi-P-P4D to monocytoid U937 and OV-MZ-6 cells was shown using 
the natural ligand of uPAR, pro-uPA, or a soluble form of uPAR, suPAR, as competitors. The 
213Bi-P-P4D showed superior binding to OV-MZ-6 cells in vitro, and accumulation of 213Bi-P-
P4D in tumor tissue was shown by biodistribution analysis in mice bearing i.p. OV-MZ-6-
derived tumors. Gelofusine reduced the kidney uptake of 213Bi-P-P4D by 50%. In conclusion, 
ovarian cancer cells overexpressing uPAR were specifically targeted in vitro as well as in vivo 
by 213Bi-P-P4D, and the kidney uptake was reduced by gelofusine. 
An additional study also using 213Bi has been published by Song et al. in which they 
investigated the pharmacokinetics, toxicity and in vivo stability of 213Bi-PAI2, and also 
determined if a prior injection of the metal chelator Ca-DTPA or lysine would reduce the 
toxicity by decreasing the renal uptake (Song et al., 2007). Two different chelators (CHX-A"-
DTPA and cDTPA) were used for the preparation of the 213Bi-PAI2 conjugate; for i.p. 
administration in mice and ear vein injection in rabbits. Neither the mice nor the rabbits 
displayed any short term toxicity over 13 w at 1,420 MBq/kg and 120 MBq/kg 213Bi-PAI2, 
respectively. The kidney uptake was markedly decreased (threefold) by blocking with 
lysine. Nephropathy caused by radiation was observed at 20–30 w in the mice, whereas 
severe renal tubular necrosis was detected at 13 w in the rabbits. In conclusion, the 
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nephropathy was the dose-limiting toxicity, and lysine was effective in reducing the uptake 
in the kidneys. Maximum tolerated doses were 350 and 120 MBq/kg for the mice and 
rabbits, respectively. The same research group has earlier shown the in vitro cytotoxicity and 
in vivo inhibition of tumor growth in breast, prostate, pancreatic, and ovarian cancer (Allen 
et al., 2003; Li et al., 2002; Qu et al., 2005; Ranson et al., 2002; Song et al., 2006). 
5.4 90Y(or 177Lu)-DOTA-biotin-streptavidin-CC49 
Owing to efforts at developing strategies for RIT against ovarian cancer (Alvarez et al., 2002) 
the same research group also investigated pretargeted RIT in an i.p. tumor model (LS174T) 
using four CC49 anti-tumor-associated glycoprotein 72 (TAG-72) single-chain antibodies 
linked to streptavidin as a fusion protein (CC49 fusion protein) (Buchsbaum et al., 2005). A 
synthetic clearing agent was administered i.v. one day later to produce hepatic clearance of 
unbound CC49. A low molecular weight radiolabeled reagent composed of biotin 
conjugated to the chelating agent 7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid 
(DOTA) complexed with 111In-, 90Y-, or 177Lu was injected four hours later. The 
radiolocalization to tumor sites was superior with i.p. administration of radiolabeled DOTA-
biotin as compared to i.v. administration. Imaging and biodistribution studies showed good 
tumor localization with 111In- or 177Lu-DOTA-biotin. Tumor localization of 111In-DOTA-
biotin was 43% ID/g (percentage of injected dose per gram) and 44% ID/g at 4 and 24 hours 
with the highest normal tissue localization in the kidney with 6% ID/g at 48 and 72 h. 90Y-
DOTA-biotin at doses of 14.8–22.2 MBq or 177Lu-DOTA-biotin at doses of 22.2–29.6 MBq 
produced significant prolongation of survival compared with controls (p = 0.03 and p < 
0.01). The conclusion of the study was that pretargeted RIT using regional administration of 
CC49 fusion protein and i.p. 90Y- or 177Lu-DOTA-biotin is a therapeutic strategy in the 
LS174T i.p. tumor model and that this strategy may be applicable to humans. LS174T is a 
human colon cancer cell line, but as it was used in an i.p. setting in this study together with 
CC49 (which reacts with the tumor-associated glycoprotein TAG-72, expressed by the 
majority of common epithelial tumors) we think it is relevant to present the results. 
5.5 177Lu-Pertuzumab and 177Lu-Affibody 
Lutethium-177-Pertuzumab has been used for disseminated HER-2-positive micrometastases 
(Persson et al., 2007), and showed good targeting in mice bearing HER-2-overexpressing 
xenografts. Absorbed radiation dose in tumors was more than 5 to 7 times higher than that in 
blood and in any normal organ. 177Lu-Pertuzumab delayed tumor progression compared with 
controls (no treatment, p < 0.0001; Pertuzumab, p < 0.0001; and 177Lu-labeled irrelevant mAb, p 
< 0.01). Adverse side effects of the treatment could not be detected. In conclusion, the results 
support the possibility using 177Lu-Pertuzumab in clinical studies. 
In a study by Tolmachev et al. a 177Lu-labeled anti-HER-2 affibody molecule (ZHER2:342) 
targeting xenografts was used (Tolmachev et al., 2007). Due to the small size (~7 kDa) of the 
affibody molecule rapid glomerular filtration and high renal accumulation occurred. 
Reversible binding to albumin reduced the renal excretion and uptake though. The affibody 
molecule (ZHER2:342)2 (i.e. dimeric) was fused with the albumin-binding domain (ABD) 
conjugated with the isothiocyanate derivative of CHX-A''-DTPA and thereafter labeled with 
177Lu. Fusion with ABD caused a 25-fold reduction of the renal uptake in comparison with the 
non-fused dimer molecule (ZHER2:342)2. The biodistribution showed high uptake of the 
conjugate in HER-2-expressing tumors. Treatment of SKOV-3 microxenografts (having a high 
HER-2 expression) with 17 or 22 MBq 177Lu-CHX-A''-DTPA-ABD-(ZHER2:342)2 prevented 
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formation of tumors completely. In LS174T xenografts (having a low HER-2 expression), this 
treatment resulted in a small but significant increase of the survival. In conclusion, fusion with 
ABD improved the in vivo biodistribution and indicated 177Lu-CHX-A''-DTPA-ABD-(ZHER2:342)2 
as a candidate for the treatment of disseminated tumors having high HER-2 expression. 
5.6 131I-A5B7 
In a large animal study of human tumors in cyclosporin-immunosuppressed sheep, by 
Turner et al., evaluation and measurement of tumor uptake of 131I-mAbs was done (Turner 
et al., 1998). Human cancer cells were orthotopically inoculated (~107 cells): SKMEL 
melanoma subcutaneously; LS174T and HT29 colon carcinoma into bowel, peritoneum and 
liver; and JAM ovarian carcinoma into the ovary and peritoneum. The tumor xenografts 
grew within 3 w and generally maintained their histological appearance, a few tumor 
deposits showing some degree of dedifferentiation though. Regional lymph node metastases 
were shown for xenografts from the melanoma and ovarian carcinoma. An anti-CEA mAb 
(A5B7) labeled with 131I was administered intravenously. The peak uptake at 5 d in 
orthotopic tumors in the gut was 0.027% ID/g and 0.034% ID/g in hepatic metastases with 
tumor-to-blood ratios of 2.0–2.5. The non-specific uptake in melanoma tumors was 0.003% 
ID/g. In conclusion, the uptake of 131I-mAb in human tumors was comparable to the uptake 
observed in patients, and this sheep model may therefore be more realistic than mice 
xenografts for prediction of the efficacy of RIT.   
6. Clinical studies 
Several clinical protocols have been reported on during the past twenty years, although 
almost all of them have been small phase I radiopharmaceutical biokinetics and absorbed 
dose-finding studies (Alvarez et al., 2002; Jacobs et al., 1993; Macey et al., 1999; Meredith et 
al., 1996, 2001; Van Zanten-Przybysz et al., 2000,2001), or phase I/II studies with no controls 
or at best matched historical cases (Epenetos et al., 1987, 2000; Hird et al., 1990; Nicholson et 
l., 1998; Stewart et al., 1989a, 1989b). Tumor stage and degree of advanced disease have 
varied greatly between, and also within, these studies as have the used targeting constructs 
and the choice of radionuclide. Albeit, these studies are important as they have provided us 
with the necessary starting hubs to the scaffold of knowledge that needs to be acquired. The 
major exception from this is the only randomised phase III study reported by Verheijen et al. 
(Verheijen et al., 2006). Despite its negative results it still holds as the major publication so 
far on intraperitoneal (i.p.) radioimmunotherapy for ovarian cancer and also stresses the 
importance of performing randomized studies. This study was spurred by the positive 
findings in a non-randomized phase I/II trial (Epenetos et al., 2000; Nicholson et al., 1998), 
where prolonged disease free and long term survival was described after one i.p. treatment, 
using 90Y labeled murine HMFG1 antibody, in patients that had received a complete 
response on standard treatment (surgery and primary chemotherapy). Prior to these reports, 
a few other small clinical studies using different radionuclides and targeting constructs, had 
likewise suggested a possibly better treatment effect of i.p. radioimmunotherapy, correlating 
inversely with size of residual disease; 131I (Epenetos et al., 1987; Crippa et al., 1995; Stewart 
et al., 1989a, 1989b); and 186Re (Jacobs et al., 1993).    
Thus, the Verheijen study (Verheijen et al., 2006) finally recruited 447 patients between 
February 1998 and January 2003, with ovarian cancer (FIGO stage Ic-IV) to evaluate if a 
single i.p. infusion of 25 mg of the ǃ-particle emitter 90Y conjugated to the murine HMFG1 
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antibody could prolong survival in patients in complete clinical response (physical 
examination and CT-scan and CA-125) after surgical debulking and finishing standard 
platinum containing chemotherapy and, importantly, with a macroscopically negative 
second-look laparoscopy. However, contrary to the beliefs from the pre-studies this large 
prospective randomized study failed to demonstrate any survival benefit. Using Cox 
proportional hazards analysis of survival, no difference was found, after a median follow-
up of 3.5 years 70/224 patients had died in the active treatment arm compared with 61/223 
in the control arm. Also time to relapse was similar between groups and 104/224 active 
treatment patients experienced relapse compared with 98/223 of controls.  
Although the study was carefully planned and well conducted and performed one should 
consider the following points which could have contributed to conceal positive effects of the 
active treatment. A) Peritoneal adhesions in up to an entire quadrant did not exclude 
patients in this study, which could potentially result in a significant underdosing of ≤ 25% of 
the abdominal cavity. Further, the adhesions were assessed by laparoscopy, CT scan or 
isotope diffusion scan, where only the latter can allow a solid enough assessment of 
adhesions and to discern between one or two quadrants of adhesions. Importantly, it is 
unclear if patients (no adhesions versus one quadrant with adhesions) were stratified 
between each treatment arm. B) A possible skewing of patients with more advanced disease 
characteristics to the treatment arm is evident, e.g. in the active treatment arm there were 8% 
more patients with residual disease after initial surgery (44.2% vs. 35.9%) and there were 3% 
more stage III and IV patients in the treatment arm which also had a higher mean CA-125 
level after laparoscopy (never explained). Furthermore, 7% more patients in the standard 
arm received consolidation chemotherapy (19.7% vs. 12.5%). C) Regarding the 
radioimmunocomplex and their antigenicity towards the cancer cells one may note that the 
overall antibody mass of 25 mg may have been insufficient to provide a concentration 
gradient to help “push” the radiolabeled antibody into the tumors. This can be contrasted to 
the 250 mg/m2 of cold antibody used with Zevalin or the 450 mg total antibody dose used 
with Bexxar. As a multi-center study the radiolabeling process was by necessity performed 
by each institution and although a radiolabeling efficiency of 95% was confirmed with thin-
layer chromatography, a potential loss of affinity of the antibody for the antigen, as a result 
of the radiolabeling process was not addressed. And lastly; D) The impact of a ≤60% MUC1 
staining for 18% of the patients in the treatment arm is grossly unknown.  
Although no survival benefit for 90Y-HMFG1 i.p. instillation as consolidation treatment for 
epithelian ovarian cancer was found, an improved local control of i.p. disease was reported 
on in a pattern of failure analysis (Oei et al., 2007). Of the 104/224 treatment arm and 98/223 
control arm relapses, there were significantly fewer i.p. (40 vs. 69, p < 0.05) and more 
extraperitoneal (47 vs. 13, p < 0.05) relapses in the treatment arm. Correspondingly, time to 
i.p. recurrence was significantly longer (53.4 vs. 46.4 months, p = 0.0019) and time to 
extraperitoneal recurrence was significantly shorter for the treatment arm (51 vs. 63.6 
months, p < 0.001).  
Thus, the main negative result of the Verheijen study balances back somewhat, in that, some 
treatment effects can be seen locally i.p. with a delaying of local relapses which, however, 
could not translate into an effect on survival. Bearing in mind the above listed concerns, it is 
from our research group’s perspective (the Targeted Alpha Therapy Group, 
www.TAT.gu.se), tempting to argue that the failure of the treatment could simply be 
explained by the choice of radionuclide, i.e. when treating microscopic disease with high 
energy ǃ-particles emitted from 90Y, the electron will have too long a range in order to 
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deliver high enough energy to the cancer cell nuclei. It has been modelled that high energy 
ǃ-particle emissions will not deposit large amounts of radiation energy into small 
microscopic tumor spheroids. 
 
 
Fig. 1. Consecutive anteroposterior decay corrected scans (Ǆ-camera) of the abdominal and 
thoracic area of a patient in the study by Andersson et al., 2009. The thyroid uptake, which is 
indicated by a region of interest in each panel, was not blocked in this patient. Images were 
acquired at 1.5 (top left), 5 (top right), 11.5 (bottom left), and 19.5 (bottom right) hours after 
infusion of 211At-MX35 F(ab’)2. The figure is reprinted by permission of the Society of 
Nuclear Medicine from Andersson H, Cederkrantz E, Bäck T, et al. Intraperitoneal ǂ-particle 
radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-
MX35 F(ab´)2 – a phase I study. J Nucl Med 2009;50:1153–1160. 
So far, the only clinical study using an ǂ-particle emitter, 211At, for treating ovarian cancer 
has been performed at our institution (Andersson et al., 2009). In a phase I study the 
pharmacokinetics and toxicity of ǂ-RIT using 211At- MX35 F(ab’)2, in 9 patients with 
relapsed ovarian cancer was studied after 2nd or 3rd line of chemotherapy. Laparoscopy to 
exclude presence of macroscopic tumor growth or adhesions was performed prior to 
infusion with 20.1–101 MBq (0.54–2.73 mCi)/L 211At-MX35 F(ab’)2 via a peritoneal catheter. 
The study demonstrated that it is possible to achieve therapeutic absorbed doses in 
microscopic tumors without significant toxicity using up to 101 MBq. The potential thyroid 
toxicity of 211At could be successfully blocked by potassium perchlorate/iodide, (unblocked 
thyroid, 24.7 ± 11.1 mGy/(MBq/L); blocked thyroid, 1.4 ± 1.6 mGy/(MBq/L)). Two patients 
have no evidence of disease at 39 and 72 months. A multicenter, phase II study is currently 
being planned, intended as an upfront adjuvant treatment for a patient population that has 
received cytoreductive surgery and chemotherapy. 
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6.1 Tolerability and toxicity 
Generally the side effects have been mild, maximum tolerated doses (MTD) depends both 
on the nuclide used and the specific construct. The highest used activities can be infused 
using 131I constructs up to 5–6 GBq have been infused using different antibodies, but due to 
a long half-life (8 days) the bone marrow suppression have been evident (Epenetos et al., 
1987; Crippa et al., 1995; Stewart et al., 1989a, 1989b). The long half-life and gamma emission 
are also a concern regarding the unintentional irradiation of staff, relatives and other 
patients. In modelling bone marrow absorbed doses (Buchsbaum et al., 1999) using the 
CC49 antibody, and based on limiting the bone marrow absorbed dose to 2 Gy, the 
maximum possible administered activity of each of the following radionuclide was 
calculated: 188Re: 6.2 GBq (167.6 mCi), 166Ho: 4.1 GBq (110.8 mCi), 177Lu: 3.9 GBq (105.4 mCi), 
186Re: 2.6 GBq (70.2 mCi), 131I: 2.2 GBq (59.5 mCi), and 90Y: 1.3 GBq (35.1 mCi). Thus, 188Re 
was found to deliver the lowest RM absorbed dose, primarily because it had the shortest 
half-life, whereas 90Y delivered the highest RM dose (high energy, long path-length).  
For 90Y a variation in MTD depending on the used antibody, from 370 MBq with B72.3 
(Rosenblum et al., 1999) up to 895 MBq with CC49 (Alvarez et al., 2002) is described. Prior to 
the large phase III study, a MTD of 685 MBq was found (Hird et al., 1990; Maraveyas et al., 
1994; Stewart et al.,1990) for 90Y using the HFG1-antibody with the bone marrow as dose 
limiting organ.  Subsequently an activity of 666 MBq was used (Nicholson et al., 1998; 
Verheijen et al., 2006), the most common side effects of nausea, fatigue, arthralgia, myalgia 
and abdominal discomfort were transient and mainly mild. The expected bone marrow 
toxicity was evident as thrombocytopenia with as much as 24% of the patients experiencing 
more than grade 3 toxicity, peeking at 6 weeks after treatment and a few cases 2,4% lasting 
until 6 months after treatment (Verheijen et al., 2006). 
Two combined modality treatment protocols have been reported with subcutaneous IFN ǂ2b 
and i.p. paclitaxel (100 mg/m2), combined with i.p. 90Y-CC49, MTD of 895 MBq, (Alvarez et al., 
2002) or i.p. 177Lu-CC49-RIT (Meredith et al., 2001). The addition of IFN increased hematologic 
toxicity such that the MTD of the combination with 177Lu-CC49 was 1.5 GBq/m2 compared to 
1.7 GBq/m2. Considering the much shorter range of the emitted ǃ-particles from 177Lu (mean 
range ≈ 0.2 mm) compared to those emitted from 90Y (mean range ≈ 4 mm), 177Lu theoretically 
has a higher therapeutic index than 90Y for a microscopic disease, due to its ability to more 
specifically irradiate the tumor cells while sparing healthy tissue.  
Strategies to increase the tumor activity and decrease the activity in dose limiting organs 
have been tested also in small clinical studies. Firstly, data have been presented using EDTA 
as an effective myeloprotective drug to suppress the bone uptake (Rosenblum et al., 1999). 
Continuous i.v. infusion of EDTA immediately before i.p. administration of up to 1,665 MBq 
90Y-B72.3 presented the expected dose-limiting toxicities of thrombocytopenia and 
neutropenia but at a higher MTD, and analysis of biopsies demonstrated that the bone and 
marrow content of the 90Y was 15-fold lower (<0.001% ID/g) in the group receiving EDTA 
infusion. Secondly, the concept of pretargeted RIT based on the avidin-biotin system, was 
evaluated in 38 patients (Grana et al., 2004). A three-step protocol: biotinylated mAbs and 
avidin were i.p. injected (first and second step), and 12–18 h later 90Y-biotin (either i.v. or 
i.p.) was injected as the third step. Sixteen were treated by i.p. injection only, whereas 22 
patients received the combined treatment (i.v. + i.p.), doses ranged from 370 to 3,700 MBq of 
90Y-biotin. Both regimens were well tolerated, but two patients showed temporary grade III–
IV hematologic toxicity. In conclusion, excellent tolerability and a good potential therapeutic 
role of pretargeted RIT in advanced ovarian cancer.  
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7. Radiation dosimetry in the clinical situation 
Dosimetry is needed to optimize the amount of radiopharmaceutical that should be 
administered to the patient (Palm et al., 2011). This involves estimating the maximum 
administered radioactivity possible at which critical normal organs reach an acceptable 
degree of toxicity. Dosimetric calculations are mostly only needed for a few critical normal 
organs. Derived organ absorbed radiation doses, combined with the knowledge about 
tolerance absorbed doses, provide a guide for estimating the maximum tolerable activity 
(MTA) that should be given. This approach has been applied in the therapy with ǃ-particle–
emitting radiopharmaceuticals when tolerance absorbed doses for critical normal organs 
have been established. An example is the therapy with 177Lu-octreotate, in which the 
administered activity is based on dosimetry for the kidneys (Garkavij et al., 2010). The 
clinical experience with ǃ-particle emitters and estimation of tolerance absorbed doses could 
possibly be used to predict the outcome for the therapy with ǂ-particle emitters. A first 
correction should then be made for the higher relative biological effectiveness (RBE) of ǂ-
particles. In the first clinical studies, an RBE of 5 has been applied for the estimation of 
equivalent absorbed doses (Andersson et al., 2009; Bruland et al., 2006; Sgouros et al., 1999). 
The concept of RBE and the uncertainties of its precise value for ǂ-particles are still under 
debate and investigated. The weighting factors applied for the estimation of the effective 
absorbed dose (where a factor of 20 often is recommended by regulators for ǂ-particle 
radiation) should not be used for predicting therapeutic efficacy and toxicity in patients 
undergoing radionuclide therapy. These weighting factors were conservatively derived for 
the stochastic effects and were never meant for use in estimating the deterministic effects 
relevant for therapy. The clinical experience using ǂ-particles is still very limited, and no 
tolerance absorbed radiation doses in humans have been determined yet. The current 
knowledge is therefore limited to in vitro and in vivo studies. For current and planned 
clinical studies of ǂ-particle–emitting radiopharmaceuticals, it is therefore very important to 
gain more insight into the toxic effects of ǂ-particles and its relationship to absorbed dose 
for different organs. The tolerance absorbed doses found for ǂ-particles could then 
gradually become established and used for the treatment planning of patients. 
Besides the special challenges regarding ǂ-particles, the establishment of pharmacokinetic 
data for dosimetry calculations does not differ from that of the more conventional ǃ-particle 
therapies. Nuclear medicine imaging is often used for the quantification of the dosimetric 
calculations. Much software have been developed for the calculation of the absorbed 
radiation doses to organs and tumors based on serial 3D imaging and anatomical 
information from computed tomography (CT) or magnetic resonance imaging (MRI) 
(Sgouros et al., 2008). Accurate quantification of Ǆ-camera and positron-emission 
tomography (PET) images and measurements of for example the radioactive blood content 
over time, are also becoming increasingly important for many diagnostic nuclear medicine 
procedures. Repeated sample measurements using, for example, a gamma-well counter can 
provide valuable pharmacokinetic data that allow for accurate absorbed dose calculations. 
Blood and urine sampling is often possible for patients undergoing therapy. Repeated 
sampling of peritoneal fluid has also been reported (Andersson et al., 2009). In principle, 
measurements or images of biopsies from organs of interest would be valuable (Bäck et al., 
2010), but the increased dosimetric accuracy gained must be weighed against the discomfort 
such invasive procedures cause the patient. Simple, non-invasive methods using uptake 
probes can also provide important information on the pharmacokinetics for an individual 
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patient. Gaze et al. have demonstrated the usefulness of such an approach for patient 
dosimetry following 131I-MIBG treatments (Gaze et al., 2005).  
Imaging using a Ǆ-camera is commonly used for quantifying the biodistribution of 
therapeutic radiopharmaceuticals. A prerequisite, of course, being the presence of emitted Ǆ-
photons, characteristic X-ray, or bremsstrahlung radiation. The image quality depends on 
photon energy, photon yields, energy settings, and appropriate matching of collimator and 
photon energy. The decay chains of the ǂ-particle emitters used hitherto in clinical studies 
(225Ac, 213Bi, 211At, and 223Ra) all include emissions of photons useful for Ǆ-camera imaging. 
However, the spatial resolution of Ǆ-camera images is inferior to what is needed to resolve 
activity distributions within organ compartments or in small tumors. Administered activity 
and the presence of photons are also much lower compared to the diagnostic situation, 
resulting in a low signal-to-noise ratio. The possibility of serial Ǆ-camera imaging of patients 
receiving ǂ-particle therapy is therefore limited for providing quantitative data for 
dosimetry of whole organs. Low count rates make the preferred 3D SPECT (three 
dimensional single photon-emission computed tomography) imaging of the radionuclide 
distribution very time consuming. Serial imaging might therefore be restricted to planar 
imaging with possibly lower accuracy for the quantification of radioactivity. Such planar 
images can provide useful quantitative information, and the accuracy can also be increased 
by using co-registration with CT images (Sjögren et al., 2002).  
A focus committee of the Society of Nuclear Medicine provided a review in 1995 of the 
different factors affecting quantitative SPECT (Rosenthal et al., 1995). The field has 
developed since then, but the main factors that affect the quantification using SPECT remain 
the same. Many factors influence the accuracy of the quantification of PET/CT images and 
include: correction for attenuation, noise, image resolution, and ROI (region of interest) 
definitions (Alessio et al., 2010; Boellard et al., 2004; Kinahan et al., 1998). Regarding all 
quantifications, it can be very useful to perform phantom measurements mimicking the 
patient situation as good as possible. Measurements of that kind can help in selecting the 
parameters for imaging or probe sessions as well as providing indications of the accuracy 
that possibly can be obtained (He et al., 2005). 
7.1 Tumor and critical organ absorbed doses 
Although the maximum amount of administered activity possible is directly related to the 
absorbed radiation dose to the critical organs, the therapeutic efficacy is determined by the 
absorbed dose to the tumors. If a low tumor absorbed dose can be expected, the therapy 
might not be justified. The tumor absorbed dose should therefore, if at all possible, be 
estimated before treatment. The visualization and quantification using a Ǆ-camera can at 
best give an estimate of the radiopharmaceutical uptake in the organ as a whole and in large 
tumors. The determination of absorbed radiation dose to sub-organ compartments or to 
small tumors or infiltrate cancer cells is though seldom possible. 
Estimating the absorbed dose to tumors following ǂ-particle therapy is particularly difficult. 
Because the targeted tumors often are too small to be detected, at best indirect methods can 
be used for approximating the absorbed radiation dose. Using antibody or peptide-based 
therapies, this approximation can for example involve in vitro studies on the binding 
kinetics to antigens or receptor sites for the relevant cancer cell type. Using radionuclides 
having a decay chain including ǂ-particle–emitting daughters, studies would involve 
investigating the retention of daughter radionuclides on or in the vicinity of the cancer cells. 
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Microdosimetry based on such in vitro studies could then provide the basis for 
investigations of the probability for eradicating or stopping or retarding the growth of the 
tumors. The theoretical basis for such dosimetry has recently been described by Sgouros et 
al. (Sgouros et al., 2011). 
The complexity of the studies and calculations involved for the absorbed dose is 
considerable, particularly when translating the results to the individual patient for an 
outcome prediction. This initial complexity should not though prevent formulation of a first, 
although perhaps rough, estimate. Such estimates, including best-guess information on 
tumor spread and overall tumor burden, targeting ability, and the amount of delivered 
radioactivity, will often provide good insight into the potential usefulness of the treatment 
approach. 
As for radionuclide therapies using ǃ-particle emitters, the absorbed dose to critical organs 
often determines the MTA. The common aim should therefore be to maximize the 
administered activity to near the level of toxicity for these organs, even for therapies using 
ǂ-particles. Therapy planning should include calculation of expected organ absorbed doses 
(Gy) per administered activity (Bq) to identify the optimal amount of activity to be 
administered. The absorbed dose calculations can either be based on pharmacokinetic data 
from previous patients or preferably, data from the specific patient is used. Such data could 
be generated by tracer studies of the actual radiopharmaceutical or a substitute with similar 
pharmacokinetics. If a fractionated or repeated therapy is to be used, the generation of 
pharmacokinetic data from each administration should be used for re-planning the 
remainder. However, differences can arise in the pharmacokinetics between the therapeutic 
radiopharmaceutical and the tracer or between subsequent therapy sessions, and methods 
should therefore be established to detect such changes. 
7.2 General considerations 
The clinical studies using targeted ǂ-particle therapy have their origin in previously 
established strategies involving ǃ-particle emitters. It is assumed that the significantly 
shorter track range of the ǂ-particles compared to ǃ-particles provides a therapeutic 
advantage in that the critical normal organs to a high degree will be spared and a higher 
absorbed radiation dose to microscopic tumors will be reached. An illustration of this fact is 
223Ra therapy for example, in which the bone marrow is less irradiated compared to 
therapies using ǃ-particle emitters. Radium-223 binds to the skeleton, resulting in a high 
absorbed dose to the bone surfaces while the absorbed radiation dose to the bone marrow 
remains relatively low. Consequently, the hematologic toxicity is therefore limited. 
If shifting from a ǃ- to an ǂ-particle emitting radiopharmaceutical, the dosimetry differs not 
only due to the different particles emitted but also due to differences in half-lives and the 
biokinetics of the free radionuclide. When, for example, using 211At-conjugates, 211At can be 
set free and be taken up in the thyroid as a result of the natrium iodine symporter (NIS) 
receptor expressed at the thyroid cells. This process is very similar to that which occurs 
when iodine-based conjugates are used and iodine is set free and taken up by the NIS 
receptor. In both of the clinical studies using 211At, blocking agents like potassium 
perchlorate were used to reduce the uptake in the thyroid cells. This method is well known 
for iodine-based therapies, and both the normal uptake of iodine in the thyroid and the 
blocking effect of, for example, potassium iodide are well established. Regarding 211At, the 
blocking effect can not be considered well established, and careful monitoring is therefore 
necessary for any unwanted uptake in the thyroid despite the use of blocking agents.  
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The physical half-life of ǂ- and ǃ-particle emitters used should ideally be matched with the 
kinetics of the targeting approach. The relatively short half-lives of the ǂ-particle emitters 
211At and 213Bi could in general be a disadvantage therefore, but are a good match for the 
loco-regional therapies such as intraperitoneal. Most of the decays will occur within the 
intraperitoneal cavity before the substance is distributed throughout the body. To be able to 
achieve optimal therapeutic efficacy the maximum safe amount of activity should be 
administered to the patient. The determination of the MTA is typically sought for a patient 
population but should ideally be estimated for each individual patient as mentioned above; 
thus, patient-specific dosimetry is needed.  
Taking a control image with an analogue is relevant for ovarian cancer. In this case, it is 
important to determine if the infused radiopharmaceutical can disperse throughout the 
peritoneal cavity and access all potential microscopic tumors on the peritoneal lining. 
Leakage control, i.e., determining the lymphatic flow out from the peritoneal cavity, can 
also be done using an analogue by monitoring the activity concentration in blood over 
time. Such control images helps manage bone marrow absorbed doses. Pharmacokinetic 
data show that the variation in absorbed dose to bone marrow among patients is around 
20% (Andersson et al., 2009). If the absorbed dose to the bone marrow determines the 
MTA, then a tracer study could be used to estimate the patient-specific MTA. However, 
since the peritoneum might determine the MTA for intraperitoneal therapy, only the 
activity concentration in the peritoneal fluid is probably needed to establish it. In this 
particular situation, the same activity concentration in the injected solution for all patients 
can be reasonable, but it is valid only if the patients are free from ascites at the time of 
injection. 
The phase I study on ovarian cancer has generated interest in an adjuvant-targeted -
particle therapy of earlier-stage cancer patients (Andersson et al., 2009). This population 
would by necessity include patients who would remain disease-free even without the 
adjuvant therapy. In such settings, it is relevant to include stochastic and/or long-term risks 
such as secondary cancers and dysfunction of the peritoneum in the justification for the 
therapy. In this particular case, it is advised that calculation of the equivalent doses to all 
relevant organs is done, including a conservative estimation of the RBE for ǂ-particles. 
8. Future perspectives 
The mortality of EOC has not decreased during the past decades, despite a decline in 
incidence and an intensification of treatment has occurred. The majority of the patients are 
diagnosed at an advanced stage and most of them will therefore succumb, suffering from 
abdominal complications. Using present diagnostics, the screening for early stage EOC has 
not been successful, but efforts in finding proteins in serum indicating early EOC is a vision 
for future improvements in ovarian cancer survival. Additional approaches are for example 
the development of targeted treatments, resulting hopefully in higher efficacy and lower 
toxicity than present day treatments, some of which have been discussed above. Such 
targeted therapies could include substrate analogues, ligands, or antibodies, resulting in up-
regulation of receptors or surface antigens. Antibodies may exhibit a therapeutic effect on 
their own or as conjugates to toxins or radionuclides. Since the clinical situation is 
dominated by spread and complications in the abdominal cavity, such therapeutic 
techniques are primarily directed intraperitoneally. A successful intraperitoneal therapy 
may eradicate abdominal disease and complications, however, extraperitoneal metastases 
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may become revealed. Therefore, a combination of abdominal and systemic modalities is 
most likely required.  
As the current available standard treatments often fail to cure a micrometastatic disease, 
RIT, using short ranged high efficiency ǂ-particles emitted from for example 211At or 213Bi 
and depositing the radiation energy in close vicinity of the targeted cancer cells, is an 
attractive approach, possibly in combination with ǃ-particle emitters aimed at larger tumor 
cell clusters. Such procedures could then be given as a boost after initial cytoreductive 
surgery and systemic chemotherapy, primarily intraperitoneally but possibly also 
intravenously by pretargeting approaches, based for example on the avidin/streptavidin-
biotin system. A systemic adjunctive approach may be of particular value if the disease 
includes retroperitoneal vascularized metastases to the lymph nodes for example 
(Buchsbaum et al., 2005; Frost et al., 2010; Paganelli et al., 1993). Another important concept 
that could potentially improve the therapeutic index would be to use fractionated RIT, 
expectedly resulting in decreased normal tissue toxicity while retaining the therapeutic 
efficacy (Elgqvist et al., 2009b). Auger emitters could also offer an alternative to the 
radionuclides mentioned above, due to the emitted electrons being low energy (<< 1 keV), 
and therefore having a very short path length in tissue. To effectively damage the DNA the 
Auger emitter has to be incorporated into the DNA molecule though, a biological challenge 
that has to be taken into account for this type of treatment. 
The potential disadvantages with a treatment given intraperitoneally are: the i.p. catheter 
could cause pain and discomfort for the patient, the catheter could leak (and possibly 
therefore decreasing the therapeutic efficacy and causing a radiation protection problem for 
the staff), and it could cause an infection and therefore a risk of peritonitis. In order for the 
i.p. treatments to be successful, especially when using radionuclides that emit short-range 
particles such as ǂ-particles, loculation and/or adhesions are undesirable and could 
decrease the therapeutic efficacy. The potential problems of toxicity (especially bone 
marrow, kidney, peritoneum) and HAMA response always needs to be addressed. A 
number of review articles have recently been published, regarding RIT in general and RIT 
against intraperitoneal EOC in particular (Allen, 2004, 2008; Andersson et al., 2003; Chérel, 
2006; Crippa, 1993; Gadducci et al., 2005; Gaze, 1996; Goldenberg, 2002; Goldenberg & 
Sharkey, 2006; Imam, 2001; Kairemo, 1996; Kassis et al., 1996; Meredith et al., 2007; Mulford 
et al., 2005; Muto & Kassis, 1995; Oyen et al., 2007; Sharkey & Goldenberg, 2005; Zalutsky et 
al., 2007). 
Many different parameters could influence the intraperitoneal therapeutic outcome, some of 
which are: the specificity of targeting construct, the degree of antigenic expression (Moltoff 
et al., 1991), loss of immunoreactivity of the targeting construct, amount of unlabeled 
antibody, diffusion barriers for penetration of the targeting construct into cancer cell 
clusters, the choice of radionuclide (half-life and particle range), low specific radioactivity, 
and tumors located extraperitoneally. If treating a microscopic disease the choice of using ǃ-
particle emitters could be problematic due to the inability of the ǃ-particles to deliver high 
enough radiation energy to the target volume, i.e. the cancer cell nuclei. That is probably the 
reason why the clinical studies performed so far using ǃ-particles have failed when trying to 
treat microscopic diseases. 
The proof-of-concept using an intraperitoneal treatment has been shown in a phase III study 
by the Gynecologic Oncology Group that included women undergoing initial therapy for 
advanced ovarian cancer (Armstrong et al., 2006), and the advantage of i.p. compared to i.v. 
administration for the localization of radiolabeled mAbs to microscopic peritoneal disease 
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has been shown in some studies, both in animal models and for humans (Andersson et al., 
2003; Horan Hand et al., 1989; Ward et al., 1987). Finally, in order to be able to compare and 
evaluate different treatment strategies the need to conduct randomized, controlled, 
multicenter clinical studies with large enough patient numbers, enabling statistical 
significance to occur, must be emphasized and aimed at.  
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